Neurologic Complications of Hematopoietic Cell Transplantation

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1653-1663

  Openshaw, Harry ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Complications from calcineurin inhibitors; Complications from immunosuppressive drugs; Complications from supportive care and other drugs; Immune mediated complications; Neurologic complications of hematopoietic cell transplantation; Pretransplant neurologic screening

Indexed keywords

EID: 84890685949     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch107     Document Type: Chapter

References (94)

1. Guerrero A, Perez Simon JA, Gutierrez N et al. Neurological complications after autologous stem cell transplantation. Eur Neurol 1999; 41: 48-50.
2. de Brabander C, Cornelissen J, Smitt PA, Vecht CJ, van den Bent MJ. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatr 2000; 68: 36-40.
3. Verstappen CC, Koeppen S, Heimans JJ et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005; 64: 1076-7.
4. Layzer RB, Rowland LP. Cramps. N Engl J Med 1971; 285: 31-40.
5. Gryn J, Goldberg J, Viner E. Propranolol for the treatment of cyclosporine-induced headaches. Bone Marrow Transplant 1992; 9: 211-12.
6. Rozen TD, Wijdicks EF, Hay JE. Treatment-refractory cyclosporine-associated headache: relief with conversion to FK-506. Neurology 1996; 47: 1347.
7. Fischman MA, Hull D, Bartus SA, Schweizer RT. Valproate for epilepsy in renal transplant recipients receiving cyclosporine. Transplantation 1989; 48: 542.
8. D Antonio D, Di Bartolomeo P, Iacone A et al. Meningitis due to penicillin-resistant Streptococcus pneumoniae in patients with chronic graft-versushost disease. Bone Marrow Transplant 1992; 9: 299-300.
9. Verfaillie C, Weisdorf D, Haake R et al. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8: 177-84.
10. Bleggi Torres LF, de Medeiros BC, Werner B et al. Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases. Bone Marrow Transplant 2000; 25: 301-7.
11. Meyers JD. Infection in recipients of bone marrow transplants. Curt Clin Top Infect Dis 1985; 6: 261-92.
12. Kalpoe JS, van Dehn CE, Bollemeijer JG et al. Varicella zoster virus (VZV)-related progressive outer retinal necrosis (PORN) after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 467-9.
13. Sullivan FM, Swan IR, Donnan PT et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007; 357: 1598-607.
14. Palestine AG. Clinical aspects of cytomegalovirus retinitis. Rev Infect Dis 1988; 10(Suppl 3): S515-21.
15. Patchell RA, White CL, Clark AW, Beschorner WE, Santos GW. Neurologic complications of bone marrow transplantation. Neurology 1985; 35: 300-6.
16. Davis D, Henslee PJ, Markesbery WR. Fatal adenovirus meningoencephalitis in a bone marrow transplant patient. Ann Neurol 1988; 23: 385-9.
17. Drobyski WR, Knox KK, Majewski D, Carrigan DR. Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrowtransplant recipient. N Engl J Med 1994; 330: 1356-60.
18. Vu T, Carrum G, Hutton G, Heslop HE, Brennan MK, Kamble R. Human herpesvirus-6 encephalitis following allogeneic cell transplantation. Bone Marrow Transplant 2007; 39: 705-9.
19. Re D, Bamborschke S, Feiden W et al. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant 1999; 23: 295-8.
20. Rabinstein AA, Atkinson JL, Wijdicks EF. Emergency craniotomy in patients worsening due to expanded cerebral hematoma: to what purpose? Neurology 2002; 58: 1367-72.
21. Kannan K, Koh LP, Linn YC. Subdural hematoma in two hematopoietic stem cell transplant patients with post-dural puncture headache and initially normal CT brain scan. Ann Hematol 2002; 81: 540-2.
22. Hoyt R, Szer J, Grigg A. Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells. Bone Marrow Transplant 2000; 25: 1285-7.
23. Patchell RA, White CL, Clark AW, Beschorner WE, Santos GW. Nonbacterial thrombotic endocarditis in bone marrow transplant patients. Cancer 1985; 55: 631-5.
24. Shimoni A, Yeshurun M, Hardan I et al. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced. Biol Blood Marrow Transplant 2004; 10: 484-93.
25. McDonald GB, Hinds MS, Fisher LD et al. Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-67.
26. Gordon B, Lyden E, Lynch J et al. Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients. Bone Marrow Transplant 2000; 25: 79-83.
27. Haire WD, Ruby EI, Gordon BG et al. Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA 1995; 274: 1289-95.
28. Lorin S, Nierman DM. Critical illness neuromuscular abnormalities. Crit Care Clin 2002; 18: 553-68.
29. Witt NJ, Zochodne DW, Bolton CF et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991; 99: 176-84.
30. Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 1996; 40: 645-54.
31. Kamble RT, Chang CC, Sanchez S, Carrum G. Central nervous system graft-versus-host disease: report of two cases and literature review. Bone Marrow Transplant 2007; 39: 49-52.
32. Padovan CS, Yousry TA, Schleuning M et al. Neurological and neuroradiological findings in longterm survivors of allogeneic bone marrow transplantation. Ann Neurol 1998; 43: 627-33.
33. Openshaw H, Slatkin NE, Parker PM, Forman SJ. Immune-mediated myelopathy after allogeneic marrow transplantation. Bone Marrow Transplant 1995; 15: 633-6.
34. Kelly P, Staunton H, Lawler M et al. Multifocal remitting-relapsing cerebral demyelination twenty years following allogeneic bone marrow transplantation. J Neuropathol Exp Neurol 1996; 55: 992-8.
35. Padovan CS, Bise K, Hahn J et al. Angiitis of the central nervous system after allogeneic bone marrow transplantation? Stroke 1999; 30: 1651-6.
36. Parker P, Chao NJ, Ben Ezra J et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine 1996; 75: 279-85.
37. Schmidley JW, Galloway P. Polymyositis following autologous bone marrow transplantation in Hodgkin's disease. Neurology 1990; 40: 1003-4.
38. Volin L, Jarventie G, Ruutu T. Fatal rhabdomyolysis as a complication of bone marrow transplantation. Bone Marrow Transplant 1990; 6: 59-60.
39. Mulligan SP, Joshua DE, Joasoo A, Kronenberg H. Autoimmune hyperthyroidism associated with chronic graft-versus-host disease. Transplantation 1987; 44: 463-4.
40. Bolger GB, Sullivan KM, Spence AM et al. Myasthenia gravis after allogeneic bone marrow transplantation: relationship to chronic graft-versus-host disease. Neurology 1986; 36: 1087-91.
41. Lisak RP, Mitchell M, Zweiman B, Orrechio E, Asbury AK. Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies. Ann Neurol 1977; 1: 72-8.
42. Rodriguez V, Kuehnle I, Heslop HE, Khan S, Krance RA. Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 515-17.
43. Openshaw H. Peripheral neuropathy after bone marrow transplantation. Biol Blood Marrow Transplant 1997; 3: 202-9.
44. Hagensee ME, Benyunes M, Miller JA, Spach DH. Campylobacter jejuni bacteremia and Guillain- Barré syndrome in a patient with GVHD after allogeneic BMT. Bone Marrow Transplant 1994; 13: 349-51.
45. Openshaw H, Hinton DR, Slatkin NE et al. Exacerbation of inflammatory demyelinating polyneuropathy after bone marrow transplantation. Bone Marrow Transplant 1991; 7: 411-14.
46. Reece D, Frei Lahr D, Shepherd JD et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporine. Bone Marrow Transplant 1991; 8: 393-401.
47. Singh N, Bonham A, Fukui M. Immunosuppressive- associated leukoencephalopathy in organ transplant recipients. Transplantation 2000; 69: 467-72.
48. Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl 2001; 7: 937-42.
49. McKinney AM, Short J, Truwit CL et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 2007; 189: 904-12.
50. Bartynski WS, Zeigler Z, Spearman MP et al. Etiology of cortical and white matter lesions in cyclosporine-A and FK-506 neurotoxicity. Am J Neuroradiol 2001; 22: 1907-14.
51. Openshaw H, Slatkin NE, Smith E. Eye movement disorders in bone marrow transplant patients on cyclosporine and ganciclovir. Bone Marrow Transplant 1997; 19: 503-5.
52. Zoja C, Furci L, Ghilardi F et al. Cyclosporineinduced endothelial cell injury. Lab Invest 1986; 55: 455-62.
53. Pizzolato GP, Sztajzel R, Burkhardt K, Megret M, Borisch B. Cerebral vasculitis during FK 506 treatment in a liver transplant patient. Neurology 1998; 50: 1154-7.
54. Famiglio L, Racusen L, Fivush B, Solez K, Fisher R. Central nervous system toxicity of cyclosporine in a rat model. Transplantation 1989; 48: 316-21.
55. McDonald JW, Goldberg MP, Gwag BJ, Chi SI, Choi DW. Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures. Ann Neurol 1996; 40: 750-8.
56. Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant 2001; 28: 753-8.
57. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-38.
58. Freeman DJ, Laupacis A, Keown PA, Stiller CR, Carruthers SG. Evaluation of cyclosporine-phenytoin interaction with observations on cyclosporine metabolites. Br J Clin Pharmacol 1984; 18: 887-93.
59. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 1987; 317: 861-6.
60. Hall RC, Popkin MK, Stickney SK, Gardner ER. Presentation of the steroid psychoses. J Nerv Ment Dis 1979; 167: 229-36.
61. Askari A, Vignos PJ, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976; 61: 485-92.
62. Vogelsang GB, Farmer ER, Hess AD et al. Thalidomide for the treatment of chronic graftversus- host disease. N Engl J Med 1992; 326: 1055-8.
63. Fullerton P, O'Sullivan D. Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatr 1968; 31: 543-51.
64. Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984; 120: 338-41.
65. McKendry RJ, Cyr M. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients. Arch Intern Med 1989; 149: 685-9.
66. Ebner F, Ranner G, Slavc I et al. MR findings in methotrexate-induced CNS abnormalities. Am J Neuroradiol 1989; 153: 1283-8.
67. Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981; 65(Suppl 1): 89-98.
68. Devinsky O, Lemann W, Evans AC, Moeller JR, Rottenberg DA. Akinetic mutism in a bone marrow transplant recipient following totalbody irradiation and amphotericin B chemoprophylaxis. A positron emission tomographic and neuropathologic study. Arch Neurol 1987; 44: 414-17.
69. Openshaw H, Stuve O, Antel JP et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000; 54: 2147-50.
70. De La Camara R, Tomas JF, Figuera A, Berberana M, Fernandez Ranada JM. High dose busulfan and seizures. Bone Marrow Transplant 1991; 7: 363-4.
71. Woo MH, Ippoliti C, Bruton J et al. Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion. Bone Marrow Transplant 1997; 19: 845-7.
72. Pallotta MG, Velazco A, Sadler A. Ifosfamide extrapyramidal neurotoxicity. Cancer 1992; 70: 2743-5.
73. Pelgrims J, De Vos F, Van den Brande J et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000; 82: 291-4.
74. Spriano M, Clavio M, Carrara P et al. Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. Haematologica 1994; 79: 218-24.
75. Baker WJ, Royer GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991; 9: 679-93.
76. Openshaw H, Slatkin NE, Stein AS, Hinton DR, Forman SJ. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 1996; 78: 1899-905.
77. Imrie KR, Couture F, Turner CC, Sutcliffe SB, Keating A. Peripheral neuropathy following highdose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 77-9.
78. Stemmer SM, Cagnoni PJ, Shpall EJ et al. Highdose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 1996; 14: 1463-72.
79. Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990; 322: 126-7.
80. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332: 1004-14.
81. Pollera CF, Marolla P, Nardi M et al. Very highdose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer Chemother Pharmacol 1988; 21: 61-4.
82. Walther PJ, Rossitch E, Bullard DE. The development of Lhermitte's sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination. Cancer 1987; 60: 2170-2.
83. Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirtyyear- old man. Cancer 1980; 45: 764-6.
84. Price B. Anisocoria from scopalamine patches. JAMA 1985; 254: 1720-1.
85. Openshaw H. Unilateral mydriasis from ipratropium in transplant patients. Neurology 2006; 67: 914.
86. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984; 101: 92-104.
87. Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 1978; 88: 361-2.
88. Eng RH, Munsif AN, Yangco BG, Smith SM, Chmel H. Seizure propensity with imipenem. Arch Intern Med 1989; 149: 1881-3.
89. Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ. Central nervous system toxicity associated with metronidazole therapy. Ann Intern Med 1980; 93: 59-60.
90. Wade JC, Meyers JD. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med 1983; 98: 921-5.
91. Spiegal DM, Lau K. Acute renal failure and coma secondary to acyclovir therapy. JAMA 1986; 255: 1882-3.
92. Davis CL, Springmeyer S, Gmerek BJ. Central nervous system side effects of ganciclovir. N Engl J Med 1990; 322: 933-4.
93. Chrisp P, Clissold SP. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991; 41: 104-29.
94. Openshaw H. Eye movement abnormality associated with cyclosporine. J Neurol Neurosurg Psychiatry 2001; 70: 809.